Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
Go back to Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection| (NASDAQ: ACXP) | Delayed: 1.57 -0.08 (4.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.65 | 52 Week High | $ | |||
| Open | $1.63 | 52 Week Low | $ | |||
| Day High | $1.65 | P/E | N/A | |||
| Day Low | $1.56 | EPS | $ | |||
| Volume | 52,199 | |||||
